<DOC>
	<DOC>NCT01720524</DOC>
	<brief_summary>This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.</brief_summary>
	<brief_title>A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Neonates with persistent pulmonary hypertension of the newborn Age &lt;=96 hours and &gt;=34 weeks gestational age Oxygenation Index &gt;15 and &lt;60 Concurrent treatment with inhaled nitric oxide and &gt;=50% oxygen Prior or immediate need for extracorporeal membrane oxygenation or cardiopulmonary resuscitation Expected duration of mechanical ventilation &lt;48 hours Profound hypoxemia Lifethreatening or lethal congenital anomaly</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Days</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>persistent pulmonary hypertension</keyword>
	<keyword>newborn</keyword>
	<keyword>neonates</keyword>
	<keyword>iv sildenafil</keyword>
	<keyword>hypoxic respiratory failure and at risk of persistent pulmonary hypertension of the newborn</keyword>
</DOC>